Related Experiment Video
Updated: May 4, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease
Jonay Poveda1, Luis C Tabara, Beatriz Fernandez-Fernandez
1Department of Nephrology, IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid and IRSIN , Madrid , Spain.
Abstract:
The incidence of acute kidney injury (AKI) and chronic kidney disease (CKD) is increasing. However, there is no effective therapy for AKI and current approaches only slow down, but do not prevent progression of CKD. TWEAK is a TNF superfamily cytokine. A solid base of preclinical data suggests a role of therapies targeting the TWEAK or its receptor Fn14 in AKI and CKD. In particular TWEAK/Fn14 targeting may preserve renal function and decrease cell death, inflammation, proteinuria, and fibrosis in mouse animal models. Furthermore there is clinical evidence for a role of TWEAK in human kidney injury including increased tissue and/or urinary levels of TWEAK and parenchymal renal cell expression of the receptor Fn14. In this regard, clinical trials of TWEAK targeting are ongoing in lupus nephritis. Nuclear factor-kappa B (NF-κB) activation plays a key role in TWEAK-elicited inflammatory responses. Activation of the non-canonical NF-κB pathway is a critical difference between TWEAK and TNF. TWEAK activation of the non-canonical NF-κB pathways promotes inflammatory responses in tubular cells. However, there is an incomplete understanding of the role of non-canonical NF-κB activation in kidney disease and on its contribution to TWEAK actions in vivo.
Insights
Targeting TWEAK (TNF-like weak inducer of apoptosis) and its receptor Fn14 shows promise for treating acute kidney injury (AKI) and chronic kidney disease (CKD). Further research is needed to understand its role in kidney inflammation.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Acute kidney injury (AKI) and chronic kidney disease (CKD) incidence is rising globally.
- Current therapies for AKI are lacking, and CKD treatments only slow progression.
- TWEAK/Fn14 pathway is implicated in kidney injury, with preclinical and clinical evidence.
Purpose of the Study:
- To explore the therapeutic potential of targeting the TWEAK/Fn14 pathway in AKI and CKD.
- To investigate the role of non-canonical Nuclear Factor-kappa B (NF-κB) activation in TWEAK-mediated kidney inflammation.
- To enhance understanding of TWEAK's contribution to kidney disease pathogenesis.
Main Methods:
- Review of preclinical data on TWEAK/Fn14 targeting in mouse models of AKI and CKD.
- Analysis of clinical evidence regarding TWEAK and Fn14 levels in human kidney injury.
- Examination of the role of non-canonical NF-κB pathway activation in TWEAK-induced inflammatory responses.
Main Results:
- Preclinical studies indicate TWEAK/Fn14 targeting preserves renal function and reduces injury markers.
- Clinical data show elevated TWEAK and Fn14 levels in human kidney disease.
- TWEAK activates non-canonical NF-κB pathways, promoting inflammation in renal tubular cells.
Conclusions:
- Targeting the TWEAK/Fn14 axis represents a potential therapeutic strategy for AKI and CKD.
- Understanding non-canonical NF-κB activation is crucial for elucidating TWEAK's role in kidney disease.
- Further investigation into TWEAK's mechanisms in vivo is warranted for clinical translation.
More Related Videos
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Nephrons
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Chronic Kidney Disease III: Interprofessional Care

